Cytek Biosciences to Report Third Quarter Financial Results on November 8, 2021

Rhea-AI Summary

Cytek Biosciences (Nasdaq: CTKB) announced it will release its third-quarter 2021 financial results on November 8, 2021, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook. Cytek is recognized for its innovation in cell analysis technologies, specifically its Full Spectrum Profiling™ (FSP™) platform, which supports advanced cellular analysis through high-resolution and high-sensitivity tools. The company's offerings include the Aurora and Northern Lights systems, with products primarily for research use, except for limited clinical applications in China and the EU.

Positive

• Upcoming third-quarter earnings report expected on November 8, 2021.
• Management to host a conference call to discuss results and outlook.
• Innovation in cell analysis tools enhances competitive positioning.

Negative

• Products primarily restricted to research use, limiting revenue opportunities from clinical applications.

FREMONT, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com

About Cytek Biosciences
Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

Investor Relations Contact:
Carrie Mendivil/Mary Kate McDonough
Gilmartin Group LLC
investors@cytekbio.com 

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com 

FAQ

When will Cytek Biosciences report its financial results for Q3 2021?

Cytek Biosciences will report its financial results for the third quarter of 2021 on November 8, 2021, after market close.

What time is the conference call for Cytek's Q3 2021 results?

The conference call will begin at 1:30 PM Pacific Time / 4:30 PM Eastern Time on November 8, 2021.

What technologies does Cytek Biosciences specialize in?

Cytek Biosciences specializes in cell analysis solutions, particularly its Full Spectrum Profiling™ (FSP™) technology.

Are Cytek's products available for clinical use?

Cytek's products are primarily for research use, although its Northern Lights CLC system is available for clinical use in China and the EU.